Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection

References

• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Bauchner H, Fontanarosa P. Thinking of risk in the era of COVID-19. JAMA. 2020.
   PubMedGoogle Scholar
• Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020;55:2001148.
   PubMedGoogle Scholar
• Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41:457–470.
   PubMed Web of Science ®Google Scholar
• Sattar N, McInnes IB, McMurray JJV. Obesity a risk factor for severe COVID-19. Infection: multiple potential mechanisms. Circulation. 2020;142(1):4–6.
   Web of Science ®Google Scholar
• Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis. 2020;90:1.
   Web of Science ®Google Scholar
• Rogosnitzky M, Berkowitz E, Jadad AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: the COVID-19 pandemic as a case in point. JMIR Public Health Surveill. 2020;6(2):e19199.
   PubMedGoogle Scholar
• Jean SS, Hsueh PR. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther. 2020:1–5 .
   Web of Science ®Google Scholar
• Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75:1667–1670.
   Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa237
   Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166.
   PubMed Web of Science ®Google Scholar
• SE T, DJ C, RO D, et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771–779.
   PubMed Web of Science ®Google Scholar
• Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl. 1988;24:142–157.
   PubMedGoogle Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5(Suppl 1):S11–5.
   PubMed Web of Science ®Google Scholar
• Pereira BB. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. J Toxicol Environ Health B Crit Rev. 2020;23(4):177–181.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16(3):411–419.
   PubMed Web of Science ®Google Scholar
• Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981–1986.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Naghipour S, Ghodousi M, Rahsepar S, et al. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert Rev Anti Infect Ther. 2020. 1–15.
   PubMed Web of Science ®Google Scholar
• Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. Clin Pharmacol Ther. 2020. DOI:10.1002/cpt.1874
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. DOI:10.1001/jama.2020.6019
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8.
   PubMed Web of Science ®Google Scholar
• Glinsky GV. Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. Biomedicines. 2020;8:5.
   Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–84.e5.
   PubMed Web of Science ®Google Scholar
• Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. Embo J. 2020;39(10):e105114.
   PubMed Web of Science ®Google Scholar
• Kalra RS, Tomar D, Meena AS, et al. SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings. Pathogens. 2020;9:7.
   Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–92.e6.
   PubMed Web of Science ®Google Scholar
• Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 epidemic. J Med Virol. 2020;92:770–775.
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134.
   PubMed Web of Science ®Google Scholar
• Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun. 2020;111:102468.
   PubMed Web of Science ®Google Scholar
• Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.
   PubMedGoogle Scholar
• Lotteau V, Teyton L, Peleraux A, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature. 1990;348(6302):600–605.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–4804.
   PubMed Web of Science ®Google Scholar
• van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55–60.
   PubMed Web of Science ®Google Scholar
• Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26(1):42.
   PubMed Web of Science ®Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162.
   PubMed Web of Science ®Google Scholar
• Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1–116.
   PubMed Web of Science ®Google Scholar
• Chiappetta S, Sharma AM, Bottino V, et al. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes (Lond). 2020;44(8):1790–1792.
   PubMed Web of Science ®Google Scholar
• Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic. J Diabetes. 2020. DOI:10.1111/1753-0407.13053
   PubMed Web of Science ®Google Scholar
• Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020. DOI:10.1136/annrheumdis-2020-217763
   PubMed Web of Science ®Google Scholar
• Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS-CoV-2. bioRxiv. 2020.
   Google Scholar
• Spinelli FR, Ceccarelli F, Di Franco M, et al. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis. 2020;79:666–667.
   PubMed Web of Science ®Google Scholar
• Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
   PubMed Web of Science ®Google Scholar
• Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819–821.
   Web of Science ®Google Scholar
• Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020. DOI:10.1016/S1473-3099(20)30296-6
   PubMed Web of Science ®Google Scholar
• Risch HA. Early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 2020.
   Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. 105949. DOI:10.1016/j.ijantimicag.2020.105949
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382:2411–2418.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493–2502.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020.
   PubMed Web of Science ®Google Scholar
• Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020.
   PubMed Web of Science ®Google Scholar
• Bonow RO, Hernandez AF, Hydroxychloroquine TM, et al. Coronavirus disease 2019, and QT prolongation. JAMA Cardiol. 2020.
   Google Scholar
• FDA Drug Safety Communication. Safety announcement. [cited 2020 Apr 24]. Available from: https://www.fda.gov/media/137250/download
   Google Scholar
• Horby P, Landray M Statement from the chief investigators of the randomised evaluation of COVID-19 therapy (RECOVERY) trial on hydroxychloroquine: no clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. [updated 2020 June 5; cited 2020 Jul 19]. Available from: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf
   Google Scholar
• FDA. Hydroxycholoquine and chloroquine letter [updated 2020 June 15; cited 2020 Jul 19]. Available from: https://www.fda.gov/media/138945/download
   Google Scholar
• WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. [updated 2020 Jul 4; cited 2020 Jul 19]. Available from: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
   Google Scholar
• Göpel S, Bethge W, Martus P, et al. Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):635.
   PubMed Web of Science ®Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020.
   PubMedGoogle Scholar
• Remdesivir EUA letter of authorization. [updated 2020 May 1; cited 2020 Jul 19]. Available from: https://www.fda.gov/media/137564/download
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020. DOI:10.1056/NEJMoa2007764
   Web of Science ®Google Scholar
• Remdesivir EUA fact sheet for healthcare providers. [updated 2020 June 15; cited 2020 Jul 19]. Available form: https://www.fda.gov/media/137566/download
   Google Scholar
• Diaz G, Cattelan AM, Balani B, et al. Association between concomitant hydroxychloroquine use and safety and efficacy of remdesivir in severe COVID-19 patients. Presented at Virtual COVID-19 Conference, 23rd International AIDS Conference (2020). [upated 2020 Jul 10–11; cited 2020 July 19]. Available from: https://cattendee.abstractsonline.com/meeting/9307/Presentation/3945
   Google Scholar
• Pagliano P, Piazza O, De Caro F, et al. Is hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19? Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa320
   PubMed Web of Science ®Google Scholar
• ICMR, Revised advisory on the use of hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory dated 23rd March. 2020 [cited 2020 Jul 19]. Available from: https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf
   Google Scholar
• Rathi S, Ish P, Kalantri A, et al. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020. DOI:10.1016/S1473-3099(20)30313-3
   PubMed Web of Science ®Google Scholar
• Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents. 2020;55(6):105988.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. DOI:10.1056/NEJMoa2016638
   PubMed Web of Science ®Google Scholar
• Cohen MS. Hydroxychloroquine for the prevention of Covid-19 - searching for evidence. N Engl J Med. 2020. DOI:10.1056/NEJMe2020388
   Web of Science ®Google Scholar
• Khan MS, Butler J. Hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383.
   PubMedGoogle Scholar
• Avidan MS, Dehbi HM, Delany-Moretlwe S. Hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383.
   PubMedGoogle Scholar
• [cited 2020 Jul 19] Available from: https://clinicaltrials.gov/(“condition or disease”: COVID; “other terms”: hydroxychloroquine, prophylaxis)
   Google Scholar
• Galvis V, Spinelli FR, Tello A, et al. Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Arch Bronconeumol. 2020. DOI:10.1016/j.arbres.2020.05.008
   Web of Science ®Google Scholar
• Aquino YSJ, Cabrera N. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. J Med Ethics. 2020. DOI:10.1136/medethics-2020-106306
   PubMed Web of Science ®Google Scholar
• [cited 2020 Jul 19]. Available from: https://clinicaltrials.gov/(“condition or disease”: COVID-19)
   Google Scholar
• Bauchner H, Fontanarosa PB. Randomized clinical trials and COVID-19: managing expectations. JAMA. 2020.
   PubMedGoogle Scholar
• Marmor MF. COVID-19 and chloroquine/hydroxychloroquine: is there ophthalmological concern? Am J Ophthalmol. 2020. DOI:10.1016/j.ajo.2020.03.029
   Web of Science ®Google Scholar
• Kwon JB, Kleiner A, Ishida K, et al. Hydroxychloroquine-induced myopathy. J Clin Rheumatol. 2010;16(1):28–31.
   PubMed Web of Science ®Google Scholar
• Rothenberg RJ, Sufit RL. Drug-induced peripheral neuropathy in a patient with psoriatic arthritis. Arthritis Rheum. 1987;30(2):221–224.
   PubMedGoogle Scholar
• Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27(12):2927–2931.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Zhou L, Hoke A, et al. Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. Am J Hematol. 2005;78(4):306–309.
   PubMed Web of Science ®Google Scholar
• Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65(3):385–390.
   PubMed Web of Science ®Google Scholar
• Shukla S, Gultekin SH, Pearls SM. Oy-sters: hydroxychloroquine-induced toxic myopathy mimics Pompe disease: critical role of genetic test. Neurology. 2019;92(7):e742–e5.
   PubMed Web of Science ®Google Scholar
• Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173–175.
   PubMed Web of Science ®Google Scholar
• Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol. 2013;19(5):286–288.
   PubMed Web of Science ®Google Scholar
• O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, et al. American academy of ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Yusuf IH, Sharma S, Luqmani R, et al. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828–845.
   PubMed Web of Science ®Google Scholar
• Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the canadian heart rhythm society. Can J Cardiol. 2020;36:948–951.
   Web of Science ®Google Scholar
• Kapoor A, Pandurangi U, Arora V, et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19. Patients: a scientific statement from the Indian heart rhythm society. Indian Pacing Electrophysiol J. 2020;20(3):117–120.
   Google Scholar
• Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020;141(24):e906–e907.
   Web of Science ®Google Scholar
• Beauverd Y, Adam Y, Assouline B, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol. 2020. DOI:10.1111/ejh.13432
   PubMed Web of Science ®Google Scholar
• Capoluongo ED, Amato F, Castaldo G. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clin Chem Lab Med. 2020;58:1162–1164.
   PubMed Web of Science ®Google Scholar
• Afra TP, Nampoothiri RV, T M R, et al. Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. Eur J Intern Med. 2020. DOI:10.1016/j.ejim.2020.07.001
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–1520.
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45:100618.
   PubMed Web of Science ®Google Scholar
• Aromolaran AS, Srivastava U, Alí A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PLoS One. 2018;13(12):e0208321.
   PubMed Web of Science ®Google Scholar
• Traebert M, Dumotier B, Meister L, et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484(1):41–48.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811.
   Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810.
   PubMed Web of Science ®Google Scholar
• Guastalegname M, Vallone A. Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa321
   PubMed Web of Science ®Google Scholar
• Landewé RB, Miltenburg AM, Verdonk MJ, et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol. 1995;102(1):144–151.
   PubMed Web of Science ®Google Scholar
• Liao W, Schones DE, Oh J, et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat Immunol. 2008;9(11):1288–1296.
   PubMed Web of Science ®Google Scholar
• Fung KL, Chan PL. Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):2016–2017.
   PubMed Web of Science ®Google Scholar
• Knoell DL, Liu MJ. Impact of zinc metabolism on innate immune function in the setting of sepsis. Int J Vitam Nutr Res. 2010;80(4–5):271–277.
   PubMed Web of Science ®Google Scholar
• Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Med Hypotheses. 2020;142:109815.
   PubMed Web of Science ®Google Scholar
• Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9:11.
   Web of Science ®Google Scholar
• RML CB, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther. 2020;18(2):99–101.
   PubMed Web of Science ®Google Scholar
• Caprio M, Infante M, Calanchini M, et al. Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eat Weight Disord. 2017;22(1):27–41.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Infante M, Editorial RC. - Vitamin D status: a key modulator of innate immunity and natural defense from acute viral respiratory infections. Eur Rev Med Pharmacol Sci. 2020;24(7):4048–4052.
   PubMed Web of Science ®Google Scholar
• Infante M, Ricordi C, Padilla N, et al. The role of vitamin D and Omega-3 PUFAs in Islet transplantation. Nutrients. 2019;11:12.
   Web of Science ®Google Scholar
• Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12:4.
   Web of Science ®Google Scholar
• Islam MA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev. 2019;18(11):102392.
   PubMed Web of Science ®Google Scholar
• Gheita TA, Sayed S, Gheita HA, et al. Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome. Int J Rheum Dis. 2016;19(3):294–299.
   PubMed Web of Science ®Google Scholar
• Linton NM, Kobayashi T, Yang Y, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med. 2020;9:2.
   Web of Science ®Google Scholar
• McElhiney LF. Pharmacies on the frontline: responding to the COVID-19 pandemic. Int J Pharm Compd. 2020;24(4):287–295.
   PubMedGoogle Scholar
• Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: possible consequences in endemic malaria settings. Med Hypotheses. 2020;143:109912.
   PubMed Web of Science ®Google Scholar